Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of the European Academy of Dermatology and Venereology : JEADV|January 28, 2015
Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanomaM Pracht, A Mogha, A Lespagnol, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2013
Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patientsC Chabbert, H Adamski, G Guillet, et al.
British Journal of Cancer|September 19, 2007
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?C Massard, J-J Voigt, A Laplanche, et al.
European Journal of Cancer (Oxford, England : 1990)|February 10, 2012
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trialM Gross-Goupil, A Fourcade, E Blot, et al.
Bulletin Du Cancer|September 2, 2000
[Standards, Options and Recommendations (SOR) for the surveillance and the prevention of cross infections in oncology. Fédération Nationale des Centres de Lutte Contre le Cancer]B Pottecher, R Herbrecht, M P Blanc-Vincent, et al.
British Journal of Cancer|June 3, 2016
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II studyF Mouriaux, V Servois, J J Parienti, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
Presse Medicale (Paris, France : 1983)|November 10, 2000
[Infection and cancer: general information and specific questions]M Viot, M P Blanc-Vincent, J Béal, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 22, 2003
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]F Mornex, L Thomas, P Mohr, et al.
Melanoma Research|February 6, 2003
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanomaF Mornex, L Thomas, P Mohr, et al.
Pageof 5